Key result
Labetalol at doses of 150-300 mg twice daily decreased the frequency of angina attacks from 9.4 to 3.3 per week and increased exercise tolerance from 266 to 413 seconds compared to placebo.
Why the study?
Does oral labetalol improve angina frequency and exercise tolerance in normotensive patients with stable angina pectoris?
Does oral labetalol improve angina frequency and exercise tolerance in normotensive patients with stable angina pectoris?
Absolute Event Rate: 3.3% vs 9.4%
Oral labetalol at doses of 150-300 mg twice daily effectively reduces angina frequency and improves exercise tolerance in normotensive patients with stable angina.
Labetalol may reduce angina frequency and improve exercise tolerance in normotensive stable angina; leaves open confirmation in larger modern trials before practice change.
The efficacy of labetalol, an alpha and beta receptor antagonist, was evaluated in 12 normotensive patients with stable angina pectoris in a single blind dose ranging study. After a two week period of placebo treatment, labetalol was given in doses of 100, 150, 200, and 300 mg twice daily, each for two weeks. Frequency of angina attacks decreased from 9.4 (SEM 2.3)/week in the control period to 7.3 (2.8), 5.2 (2.6), 3.8 (1.8), and 3.3 (1.9)/week in the four successive treatment periods. In the same periods the number of glyceryl trinitrate tablets consumed decreased from 7.0 (2.6)/week to 5.8 (3.3), 3.9 (2.9), 2.7 (1.8), and 2.6 (2.1)/week. Maximal symptom limited treadmill exercise tests were performed three and 12 hours after dosage at each dose. Exercise tolerance (expressed as seconds of the Bruce protocol) increased from 266 (44) with placebo to 306 (44), 369 (50), 396 (48), and 413 (51) in the four treatment periods. This improvement was accompanied by a significant blunting of the heart rate and blood pressure responses to exercise. Trough point exercise tolerance did not differ significantly from that at three hours after dosage. Thus labetalol is effective as an antianginal agent at doses of 150-300 mg twice daily and is well tolerated by the normotensive patient with angina.
No takes yet. Share an insight, caveat, or question.
Upward et al. (1985) studied Stable angina pectoris (n=12). Labetalol vs. Placebo was evaluated on Frequency of angina attacks per week. Labetalol at doses of 150-300 mg twice daily decreased the frequency of angina attacks from 9.4 to 3.3 per week and increased exercise tolerance from 266 to 413 seconds compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: